It was a good start for Amylin Pharmaceuticals (NASDAQ:AMLN) on its goal of having positive operating cash flow by the end of next year, but I doubt it'll be enough to keep Carl Icahn and Eastbourne Capital from complaining. The company managed to halve its non-GAAP operating loss -- which "approximates" its operating cash flow "before working capital changes" -- from $44 million in the year-ago quarter to less than $20 million in the first quarter of this year.